ID: MRFR/HC/6927-HCR | February 2021 | Region: Global | 111 pages
Gene Therapy Market was valued USD 524 million in 2018 and expected to register a CAGR of 40.7% By 2025.
The research and development, along with increased investment in product development is driving the gene therapy market.
Acquisitions of small-scale companies by key players and a large number of ongoing clinical trials are driving the gene therapy market.
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Product, Indication, End-User|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Amgen, Inc. (US), Novartis AG (Switzerland), Spark Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), uniQure N.V. (Netherlands), Orchard Therapeutics plc (UK), Celgene Corporation (US), Bristol-Myers Squibb Company (US), Thermo Fisher Scientific Inc. (US), CEVEC (Germany), Lonza (Switzerland)|
|Key Market Opportunities||New product launches and R&D Amongst major key Players|
|Key Market Drivers||
Frequently Asked Questions (FAQ) :
Based on product, Gene therapy industry divided into kymriah, luxturna, yescarta, zolgensma, strimvelis, zynteglo, imlygic, and others. Kymriah: Novartis AG reported an annual sale of USD 28 million in 2018. Zynteglo: The drug indicated for transfusion-dependent β thalassaemia (TDT), is the second most expensive drug valued at an approximate value of USD 1.8 million. Yescarta: The drug was approved by the US Food and Drug Administration (FDA), in 2018, for the treatment of B-cell lymphoma.
The key players are investing in the manufacturing of cell and gene therapy treatments due to its target specificity. In the regional market Asia-Pacific is expected to be the fastest-growing market. On the basis of Indication The oncology segment is expected to hold the largest market share and to be the fastest-growing segment due to high prevalence of cancer and robust pipeline for cancer gene therapy.
The gene therapy market had reached a valuation of USD 524 MN in 2018.
The gene therapy market is projected to grow at approximately 40.7% CAGR during forecast period (2019-2025).
Rising technological advances and favorable government initiatives.
North America holds the largest share in the gene therapy market, followed by Europe and the Asia Pacific, respectively.
Novartis AG (Switzerland), Amgen, Inc. (US), Spark Therapeutics, Inc. (US), uniQure N.V. (Netherlands), Gilead Sciences, Inc. (US), Orchard Therapeutics plc (UK), Bristol-Myers Squibb Company (US), Celgene Corporation (US), Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), and CEVEC (Germany), are some of the major players operating in the gene therapy market.
This table of content is tentative and subject to change as the research progresses.
Please Note: Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.